Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Jacques R. Leclerc"'
Autor:
Lakshmi Padgett, Werner Hacke, Philip Teal, Barry Oemar, James C. Torner, Antoni Dávalos, Harold P. Adams, Elliot S. Barnathan, Mark B. Effron, Judith Frayne, Jacques R. Leclerc
Publikováno v:
Stroke. 39:87-99
Background and Purpose— A previous randomized, placebo-controlled, double-blind study suggested that abciximab may be safe and effective in treatment of acute ischemic stroke. The current phase 3 study was planned to test the relative efficacy and
Autor:
William T. Clarke, Werner Hacke, Michael D. Hansen, Eric Bluhmki, Harold P. Adams, Jacques R. Leclerc
Publikováno v:
Cerebrovascular Diseases. 18:124-129
Background: The spectrum of neurological impairments following acute ischemic stroke is broad. The initial stroke severity predicts responses to treatment and outcomes after ischemic stroke. While clinical trials are using baseline severity as an enr
Publikováno v:
Annual Advances in Stroke Management
Although thrombolytic therapy is approved in several countries for treatment of ischemic stroke, only a small number of patients are eligible for treatment. Additional agents that could restore or improve cerebral flow are needed. Reperfusion agents
Publikováno v:
Cerebrovascular Diseases. 11:287-293
While thrombolytic therapy is approved in the United States and Canada for treatment of acute ischemic stroke, only a small number of patients are currently treated. Additional agents that could restore or improve cerebral flow are needed. Based on t
Autor:
Robert Côté, Christina Wolfson, Susan Solymoss, Ariane Mackey, Jacques R Leclerc, Denis Simard, Fabrice Rouah, France Bourque, Barbara Léger
Publikováno v:
Stroke. 31:1856-1862
Background —Increased levels of markers of hemostasis may assist in the determination of the extent of carotid occlusive disease and the identification of neurologically intact individuals at increased risk of ischemic events. Methods —We conduct
Publikováno v:
Thrombosis and Haemostasis. 81:353-357
SummarySymptoms and clinical signs individually are inaccurate for the diagnosis of DVT. However, when assessing patients with leg symptoms, clinicians have access to additional information, such as whether or not DVT risk factors are present that co
Publikováno v:
Chest. 114:115S-118S
Autor:
Jeffrey I. Weitz, Franco Piovella, Jack Hirsh, Jacques R. Leclerc, Peter Powers, Mark Levine, Jeffrey S. Ginsberg, William Geerts, Alexander G.G. Turpie, Michael Gent, Jean Neemeh
Publikováno v:
Thrombosis and Haemostasis. 74:606-611
SummaryThe optimal duration of oral anticoagulant therapy for patients with acute proximal deep vein thrombosis (DVT) is uncertain. Based on the hypothesis that a normal impedance plethysmogram (IPG) following DVT defines a group of patients at low r
Publikováno v:
Thrombosis and haemostasis. 99(5)
SummaryThe burden of thromboembolism (TE) in severe sepsis is largely unknown. We assessed the prevalence of venous and arterial TE in patients with severe sepsis over a four-week period. We performed a retrospective analysis of a pooled database of
Publikováno v:
Pharmacotherapy. 26(3)
A patient was administered drotrecogin alfa (activated) in addition to the standard of care for presumed severe sepsis and circulatory shock. Heparin-induced thrombocytopenia (HIT) and hepatic and splenic thromboses complicated her clinical course. B